Mineralys Therapeutics (NASDAQ:MLYS) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibroinflammatory diseases of the liver and kidney. The company’s proprietary platform centers on small-molecule soluble guanylate cyclase (sGC) modulation, aiming to restore normal vascular and immune cell function to address underlying drivers of chronic organ damage. Mineralys’ lead programs include MLY-402 for portal hypertension secondary to cirrhosis and MLY-127 for diabetic kidney disease, both of which have advanced into clinical studies.
Since its inception, Mineralys has built a diversified pipeline that spans from early discovery through Phase 2 development. The research team leverages in-house target validation, medicinal chemistry, and translational biology capabilities to optimize sGC modulators with differentiated pharmacokinetic and safety profiles. Beyond its lead assets, the company is exploring additional indications where impaired nitric oxide signaling and fibrosis intersect, including nonalcoholic steatohepatitis (NASH) and select rare kidney disorders.
Headquartered in Cambridge, Massachusetts, Mineralys operates research facilities in the Boston biotech hub while maintaining collaborations with leading academic institutions and contract research organizations worldwide. This geographic reach enables the company to conduct multi-center clinical trials across North America and Europe, accelerating patient enrollment and regulatory interactions. The global footprint also supports future commercial readiness in key markets.
Mineralys is led by an experienced management team with deep industry expertise spanning drug discovery, clinical development, regulatory affairs, and commercialization. The leadership includes veterans from both large pharmaceutical companies and successful biotech startups, supported by a scientific advisory board of renowned hepatology and nephrology experts. Together, they guide Mineralys toward its mission of delivering first-in-class therapies for patients with debilitating liver and kidney diseases.